The use of cationic liposomes as nonviral vehicles for the delivery of therapeutic molecules is becoming increasingly prevalent in the field of gene therapy. We have previously demonstrated that the use of the transferrin ligand (Tf) to target a cationic liposom e delivery system resulted in a significant increase in the transfection efficiency of the complex [Xu, L., Pirollo, K. 
INTRODUCTION W
ILD -TYPE (wt) p53 plays a crucial role in apoptotic pathways leading to cell death (reviewed in Bates and Vousden, 1999) . The lack of functional p53 is believed to contribute to the failure of many cancers to respond to conventional therapies (reviewed by Ruley, 1996; Roth, 1998) . For exam ple, the presence of mutant (mt) p53 has been shown to correlate with increased radiation resistance in some human tumors and cell lines, possibly because of the loss of the p53-dependent apoptotic pathway (Lee and Bernstein, 1993; O'Connor et al., 1993; McIlwrath et al., 1994; Bristow et al., 1996; Nielson and Maneval, 1998; Meng and El-Deiry, 1999) . Therefore, reestablishing wt p53 function in tumor cells may restore the p53-me-diated apoptotic pathway, resulting in more efficient treatment modalities.
Progress has been made toward developing nonviral, pharmaceutical formulations of genes for in vivo human therapy, particularly cationic liposome-med iated gene transfer systems (Felgner et al., 1995; Templeton et al., 1997; Huang and Viroonchatapan, 1999) . However, liposomal systems in general suffer from low transfection efficiencies when com pared with those observed with viral vector delivery systems. The transfection efficiency of cationic liposom es can be dramatically increased when a ligand recognizing a cell surface receptor is included in the complex. The presence of the ligand facilitates the entry of the DNA-liposome complex into the cell through the initial binding of ligand by its receptor on the cell surface, followed by internalization of the bound complex via receptormediated endocytosis (Cheng, 1996) , a highly efficient internalization pathway present in eukaryotic cells (Christiano and Curiel, 1996; Wagner, 1999) . We have previously reported that the addition of the transferrin (Tf) ligand to a cationic liposome com plex resulted in an in vitro transfection efficiency of 70-80% in squamous cell carcinoma of the head and neck (SCCHN) as compared with only 5-20% transfection by the cationic liposome com plex without Tf (L. . Transferrin receptor (TfR) levels are known to be elevated in various types of cancer cells including breast (Inoue et al., 1993) and prostate cancers (Keer et al., 1990) , even those prostate cancer cell lines derived from human lym ph node and bone metastases (Grayhack et al., 1979; Chackal-Roy et al., 1989; Rossi and Zetter, 1992) , as well as squam ous cell carcinomas (Thorstensen and Romsio, 1993; Miyamoto et al., 1994) , and correlate with the aggressive or proliferative ability of tumor cells (Elliott et al., 1993) .
Squamous cell carcinoma of the head and neck is one of the most difficult forms of cancer to treat successfully. Approximately 40,000 new cases are diagnosed in the United States each year, with more than 12,000 individuals succumbing to this devastating disease annually (Landis et al., 1998) . Despite advances in the preferred forms of therapy, i.e., surgery and radiation, and now even chem otherapy, no major improvement in efficacy and survival has occurred over the past several decades. Approximately 70% of patients with advanced disease (stage III-IV) will still die from their illness, prim arily from recurrent disease, which occurs in more than 60% of patients (Dimery and Hong, 1993) . Even 25% of those with early stage disease (stage I-II) are incurable (van Dongen and Snow, 1997) . Resistance to ionizing radiation by a subset of the tumor cells is believed to account for a significant portion of these clinical failures. Therefore, a new treatm ent modality that results in sensitization of these tumors to standard radiation therapy would have a marked effect on the clinical outcome of this disease for many patients.
In our previous report (L. , we dem onstrated that wt p53 was efficiently delivered to SCCHN tum or cells in vitro by the Tf-liposome com plex. The high-level expression of this exogenous wt p53 in the Tf-liposome-DNA-transfected cells resulted in the reversion of the radioresistant phenotype of the SCCHN cells in a DNA dose-dependent manner. In the present study, we further optimized the transferrin-cationic liposome system for systemic p53 gene therapy of SCCHN and dem onstrate that the transduced wt p53 restored wt p53 function in these cells, leading to increased radiation-induced apoptosis in a p53 DNA-depend ent manner. These findings indicate that the reversal of the radiation resistance of the SCCHN cells observed in vitro in our previous report was due to this restoration of the p53-dependent apoptotic pathway.
Most significantly, we examined the ability of transfected wt p53 to sensitize SCCHN to radiation in vivo. Our findings dem onstrate that this transferrin-cationic liposome system could preferentially deliver the p53 gene to preestablished SCCHN xenograft tumors and sensitize them to radiotherapy, resulting in long-term tumor regression in animals receiving the com bination therapy. This sensitization of SCCHN tumors, through the com bination of systemic p53 gene therapy and ionizing irradiation, has the potential for use as a new therapeutic modality for the treatment not only of initial malignancies, but also for the larger challenge of recurrent disease.
MATERIALS AND METHODS

Cell culture
Human head and neck cell line JSQ-3, derived from a tumor of the nasal vestibule that failed radiotherapy, was a generous gift from R. Weichselbaum (University of Chicago; Weichselbaum et al., 1993) . The cell line was maintained in minimum essential medium with Earle's salts (EMEM) with supplem ents as previously described (L. .
Plasmids
The Escherichia coli lacZ gene, driven by a simian virus 40 (SV40) promoter in expression plasm id pSVb, and the firefly luciferase gene driven by the cytomegalovirus (CMV) promoter in plasm id pCMVLuc, were employed as reporter genes (both from Promega, Madison, WI). The p53 expression plasmid pCMVp53 contains the 1.7-kb human wt p53 cDNA under the control of the CMV promoter, followed by the SV40 polyadenylation signal. The control plasmid pCMVpRo contains the same p53 cDNA in the reversed orientation, also under the control of the CMV promoter. All the plasmids were expanded in E. coli DH5a and purified with plasmid Mega/Giga kits (Qiagen, Valencia, CA). The purified plasmids were quantified spectrophotometrical ly with A 260 /A 280 values of approxim ately 1.95. Agarose gel (0.8%) electrophoresis confirmed that . 95% of the plasmid DNA was supercoiled.
Preparation of transferrin-liposom e-DNA complex
Cationic liposomes consisting of 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) and dioleoylphosphatidylethanolamine (DOPE) (Avanti Polar Lipids, Alabaster, AL) were prepared as previously described (L. . The final concentration of liposomes was 2 m mol/ml. Holo-transferrin (Tf, iron saturated; from Sigma, St. Louis, MO) was dissolved in pure water at 5 mg/ml. The Tf-liposome-DNA complex for in vitro experiments was prepared as described except that the serumfree medium EMEM was used instead of Hanks' balanced salt solution (HBSS) (L. . The prepared Tf-liposom e (designated LipT)-DNA com plex was used for in vitro cell transfection freshly within 1 hr of preparation, although on the basis of transfection efficiencies it was found to be stable for at least 24 hr. Agarose gel electrophoresis was employed to assess the DNA retardation by complexing with LipT.
Optimization of LipT system by luciferase assay
The LipT system was optimized for JSQ-3 transfection using the luciferase assay. JSQ-3 cells (5 3 10 4 /well) were plated in a 24-well tissue culture plate. Twenty-four hours later, the cells were washed once with EMEM without serum, and 0.3 ml of EMEM without serum or antibiotics was added to each well. EMEM (0.2 ml) with the Tf-liposome-pCMVLuc (LipT-Luc) complex containing 1.0 m g of plasmid DNA complexed with different amounts of cationic liposome and transferrin was added to the cells, usually in triplicate. After a 5-hr incubation at 37°C and 5% CO 2 , 0.5 ml of EMEM, supplemented with 20% fetal bovine serum and hydrocortisone (1 m g/ml), was added to each well. Twenty-four hours later, the cells were washed once with phosphate-buffered saline (PBS), lysed with 1 3 reporter lysis buffer (100 m l/well; Promega), and the expressed luciferase activities were measured with the luciferase assay system (Promega) on a luminometer (Xu et al., 1999) . A recom binant firefly luciferase (Promega) standard was used at each measurement so as to convert the luminometer readings of relative light units (RLU) to the amount of luciferase equivalent expressed. Protein concentrations of the cell lysates were measured with a DC protein assay kit (Bio-Rad, Hercules, CA). The results were expressed as micrograms of luciferase equivalent per milligram of total protein.
In vitro transfection of JSQ-3 cells by LipT-pSVb
A quantitative b -galactosidase colorim etric assay was employed as described previously (L. . Purified bgalactosidase (Boehringer Mannheim, Indianapolis, IN) was used as standard. The results were expressed as milliunits (mU) of b -galactosidase equivalent per milligram of total protein. For histochemical studies of Tf-liposome-pSVb transfection, 60% confluent JSQ-3 cells in a 24-well tissue culture plate were transfected for 5 hr with 1.2 m g of pSVb with or without LipT as described above. After an additional 2 days in culture, the cells were fixed and stained with 5-bromo-4-chlor o-3-indolylb -D -galactopyranoside (X-Gal), and transfection efficiency was calculated as the percentage of blue-stained cells as previously described (L. Xu et al., , 1999 .
Western blot analysis
To determine the DNA-dose response of p53 gene expression, 2 3 10 5 JSQ-3 cells/well were plated in a six-w ell tissue culture plate. After 24 hr, cells were washed once with EMEM without serum and antibiotics, transfected with 1 ml of transfection solution containing LipT-p53 or LipT-pRo containing up to 4 m g of plasmid DNA per 2 3 10 5 cells, at the ratio of 1 m g of DNA per 10 nmol of liposom e per 15 m g of Tf in EMEM. Five hours after transfection, 1 ml of EMEM supplem ented with 20% fetal bovine serum (FBS) and hydrocortisone (1 m g/ml) was added and cultured for an additional 48 hr. The transfected cells were collected and lysed in RIPA radioimmunop recipitation assay buffer (Santa Cruz Biotechnology, Santa Cruz, CA) and Western blot analysis was performed as previously described (L. Xu et al., , 1999 . For the time course of p53 gene expression, 2 3 10 5 JSQ-3 cells were transfected with 2 m g of pCMVp53 or pCMVpRo complexed with LipT. The cells were collected for Western blot analysis every 24 hr up to 5 days after transfection and applied. To analyze the radiation effect on p53 gene expression, JSQ-3 cells were transfected with LipT-p53, or LipT-pRo (2 m g of DNA per 2 3 10 5 cells per well in a six-well plate) for 2 days, then trypsinized and irradiated in suspension with graded doses (up to 6 Gy) of 137 Cs g rays in a J.L. Shepard and Associates Mark I irradiator (L. . The irradiated cells were replated and cultured for 2 or 4 days before being harvested for Western blot analysis.
p53 and radiation-indu ced apoptosis
To study p53-induced apoptosis, JSQ-3 cells were transfected with LipT-p53 or LipT-pRo (1 to 3 m g of DNA per 2 3 10 5 cells) as described above, and both the attached and floating cells were collected every day for 3 days for apoptosis staining. For radiation-induced apoptosis, the cells were transfected for 2 days, and then trypsinized and irradiated as described above. The replated cells were collected 4 days later for apoptosis staining. The collected cells were stained with the annexin V-fluorescein isothiocyanate (FITC) kit (Trevigen, Gaithersburg, MD) according to the manufacturer' s protocol. The stained cells were analyzed on a flow cytometer (FACStar; Becton Dickinson, Franklin Lakes, NJ).
In vivo gene transfection in nude mouse JSQ-3 xenograft model by intravenous injection of LipT-pSVb
The transferrin-liposome, liposome-pSVb, and pSVb DNA com plexes were prepared as previously described (L. at a ratio of 1 m g of DNA per 10 nmol of liposome per 12.5 m g of transferrin. However, sterile 5% dextrose was used in place of HBSS. The nude mouse tumor model was established by subcutaneous injection of 2.5 3 10 6 JSQ-3 cells in the flank of 4-to 6-week-old female athym ic nude mice (NCR nu/nu). pSVb DNA (30 m g) complexed with Tf-liposome in a 300-m l total volume was injected into each mouse via the tail vein, using a 1-m 1 syringe and a 30-gauge needle. In the control groups, either liposome-pSVb or pSVb DNA without liposome was injected. Two and 10 days after DNA injection, the tumors as well as mouse organs were excised, cut into 1-mm-thick slices, washed once with PBS, and fixed with 2% formaldehyde-0.2% glutaraldehyde for 4 hr at room temperature. The fixed tumor slices were washed four times with PBS, each for 1 hr, and stained with X-Gal solution plus 0.1% Nonidet P-40 (NP-40) (pH adjusted to 8.5) at 37°C overnight. The stained tum or slices were embedded and sectioned by normal histological procedures and counterstained with nuclear fast red. Four sections per tumor were examined to evaluate the b -galactosidase gene expression, as indicated by the blue-stained cells.
In vivo systemic p53 gene therapy in combination with radiation
JSQ-3 cells (2.5 3 10 6 ) were injected subcutaneously into the lower back above the tail of athymic NCR nu/nu nude mice. Seven to 10 days later, the tumors grew to approximately 40-50 mm 3 at the injection site. Freshly prepared LipT-p53 or LipT-pRo containing 8 m g of DNA in 300 m l of 5% dextrose was intravenously injected per mouse via the tail vein twice a week for a total of five injections. Forty-eight hours after the initial intravenous injection, the animals were secured in a lead restraint that permitted only the tum or area to be exposed to g irradiation, and the first fractionated dose of 2.5 Gy of 137 Cs ionizing radiation was administered. Thereafter, the animals were given 2.5 Gy every 48 hr to a total dose of 25 Gy. For com parison, a group of untransfected mice, as well as a group of mice injected with LipT-p53, received no radiation. The tumor sizes were measured weekly in a blinded manner by a third party at the Georgetown University Animal Facility. All animal experim ents were performed in accordance with Georgetown University institutional guidelines for the care and use of animals.
Histological analysis of JSQ-3 xenografts after combination treatment
Subcutaneous JSQ-3 tumors were excised from the animals at various times after the end of the treatment. The tumor tissues were formalin fixed, sectioned, and stained with H&E according to common histological procedure.
Statistical analysis
The Student t test and two-w ay ANOVA was performed with GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, CA; www.graphpad.com).
RESULTS
Optimization of transferrin-liposomes for transfection of head and neck cancer cells
LipT, the liposome complex based on cationic lipids DOTAP and DOPE with transferrin, was prepared as previously described (L. . To optimize the transfection efficiency, a plasmid designated as pCMVLuc that contains the firefly luciferase gene driven by the cytomegaloviru s (CMV) promoter was employed as reporter gene. JSQ-3 cells were transfected with different DNA-lipid-Tf ratios of LipTpCMVLuc (LipT-Luc). Figure 1 shows that transferrin significantly enhanced the transfection efficiency of cationic liposom es. Under optimal conditions, i.e., a DNA:lipid:Tf ratio of 1 m g:10 nmol:12.5 m g, luciferase was expressed at 12.5 6 1.1 m g/mg total protein, representing 1.25% total protein, 7-to 10- fold more than liposome alone without transferrin. The results agreed with our previous report (L. . This ratio was used as a basic ratio for in vivo optimization below.
In the quantitative b -galactosidase assay, the JSQ-3 cells transfected under the optimal conditions, with 0.5 m g of DNA per 10 5 cells of LipT-pSVb, expressed 15.04 6 0.60 mU/mg total protein of b -galactosidase without serum, and 10.95 6 0.15 mU/mg in the presence of serum. In histochemical studies, transfection with LipT-pSVb resulted in 70-80% of the cells being transfected (see Table 1 ). The presence of serum during transfection slightly reduced transfection efficiency, but even with serum, 40-50% of the cells stained blue, while cationic liposome without ligand gave only 10-20% transfection efficiency. These results demonstrated that using Tf as a ligand significantly increased the transfection efficiency of cationic liposomes, even in the presence of serum. a JSQ-3 cells (60% confluent), cultured in a 24-well plate, were transfected for 5 hr with 0.5 ml of transfection solution containing 1.2 m g of pSVb. After an additional 2 days in culture, the cells were fixed and stained with X-Gal. Transfection efficiency was calculated as the percentage of blue-stained cells. LipT-pSVb, transferrin-liposome-pSVb complex; Lip-pSVb, liposome-pSVb without transferrin. 
Expression of exogenous wild-type p53 protein in LipT-p53-transfected JSQ-3 cells
Western blot analysis was employed to dem onstrate that the LipT-transduc ed wt p53 was being expressed in JSQ-3 cells. As shown in Fig. 2A , transfection with increasing doses of p53 expression plasmid pCMVp53 complexed with LipT (LipT-p53) resulted in a DNA dose-dependent expression of wt p53, while no exogenous p53 expression was evident in JSQ-3 cells transfected with LipT-pRo, which carries the wt p53 cDNA in reverse orientation. Wild-type p53 was expressed 24 hr after LipT-p53 transfection and peaked on the second day (Fig. 2B) . Only traces of exogenous p53 were detected 5 days after transfection, indicating that LipT-mediated wt p53 expression was transient (Fig. 2B) . When the cells were irradiated 48 hr after LipT-p53 transfection, i.e., at the peak of exogenous wt p53 expression, the level of wt p53 protein increased with increasing doses of g irradiation (Fig. 2C) . The level of p53 protein still present even 4 days postirradiation (i.e., 6 days posttransfection) indicates that g irradiation can enhance and/or stabilize the exogenous wt p53 expression in a radiation dose-dependent manner, analogous to the situation observed in cells with naturally occurring wt p53.
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Apoptosis induced by p53 transfection and g irradiation
To examine the effect of wt p53 restoration on the induction of apoptosis, JSQ-3 cells were transfected with LipT-p53 or LipT-pRo, then stained on days 1 to 3 with annexin V-FITC, which binds specifically to phosphatidylserine present on apoptotic cells. As shown in Fig. 3 , a clear induction of apoptosis is observed with LipT-mediated wt p53 restoration, in a DNA dose-dependent manner. The percentage of apoptotic cells peaked on the second day of transfection, correlating with the levels of wt p53 expression in the cells as revealed by Western blot (Fig. 2B) . To examine the effect of irradiation on the induction of apoptosis, the transfected cells were irradiated with various doses 48 hr after transfection. Two to 4 days later, the cells were stained with annexin V-FITC and analyzed by flow cytometry. As show n in Fig. 4A , g irradiation induced a significant increase in apoptosis only in LipT-p53-transfected cells, from 18.7% (0 Gy) to 38.7% (4 Gy) and 46.4% (6 Gy) 2 days after irradiation (or 4 days after transfection). No increase was observed with untransfected (UT) cells or those transfected with LipT or LipT-pRo. This increase was also radiation dose dependent and correlated, as indicated in Fig. 4B, with the wt   FIG. 3 . LipT-p53 transfection-induce d apoptosis. JSQ-3 cells were transfected with LipT-p53 or LipT-pRo, then stained from day 1 to day 3 with annexin V-FITC, which bound specifically to phosphatidylserin e present on apoptotic cells. A clear induction of apoptosis is observed in LipT-mediated wt p53 restoration, in a DNA dose-dependent manner. p53 expression levels shown in Fig. 2C (r 5 0.9843), demonstrating that the radiation enhancement of apoptosis was proportional to the wt p53 level in cells, i.e., the more wt p53 expressed, the more apoptotic cells induced.
In vivo transfection of systemically delivered LipT-pSVb complex
To examine the ability of the Tf-containing liposomes to selectively target tumor tissue in vivo, LipT-pSVb or the pSVb plasmid alone was injected intravenously into nude mice bearing JSQ-3 subcutaneous xenografts. After either 2 or 10 days, the tumors and major organs were examined by histochemical staining with X-Gal. At 2 days, the tumors in mice injected with LipT-pSVb showed reporter gene expression representing an 
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LipT is selective, with the human xenograft being most heavily stained.
Effect of the combination of LipT-p53 and radiation treatment on JSQ-3 xenografts in vivo
Two independen t experimen ts with SCCHN (JSQ-3) xenograft tumors have been performed with similar results (Fig. 5A and B) . Mice bearing subcutaneou s JSQ-3 tumors of approxim ately 25-40 mm 3 were injected, via the tail vein, with LipT-p53 twice weekly (a total of five injections) and only the tumor areas were exposed to fractionate d doses (2.5 Gy) of g radiation, every other day to a total of 25 Gy. As shown in Fig. 5A and B, short-term radiation effects on tumor growth were evident in cells transfected using the control LipT-pRo. There was only minim al tumor growth inhibition in the animals that received LipT-p53 without radiation. In contrast, in both experiment s all the tum ors that received the combinatio n of LipT-p53 plus radiation exhibited virtually complete regression and show ed no signs of recurrence (p , 0.001). In the case of the longer maintained experiment (Fig. 5B) , the tumor-bear ing anim als in control groups had died or were humanely euthanized because of excessive tumor burden by 6 months postirradiat ion. However, the combinatio n treatment group (p53 plus irrdiation) still showed no sign of tum or regrow th (Fig. 5B) .
Histology of the small residual "tum or nodule" present in som e of the anim als, which was static at less than 10% of the original tum or volum e over the entire course of the experiment, is show n in Color Plate 2. In the mice that had received LipT-p53 plus radiation, it is evident that mostly dead and dying tum or cells, many being engulfed by macrophages, and few live tum or cells rem ain 1 day after com pletion of treatment (Color Plate 2A). In contrast, although radiation effects are evident, live nests of tum or cells are clearly visible in the mice that received LipT-pRo plus radiation (Color Plate 2B). For com parison, an untreated tumor receiving radiation alone is shown in Color Plate 2C. Color Plate 2D show s, 1 month posttreatm ent, residual tissue at the site of the original tumor in an animal that received LipT-p53 plus radiation. No live tumor cells were evident; only scar tissue and a few multinuclear Langerhan s cells were present. By 6 months posttreatment, only mature scar tissue and numerous macrophag es or Langerhan s cells in the process of surroundin g and engulfing the rem ains of the dead tumor cells, are evident in the residual tumor mass from the animal in the com bination treatment group (Color Plate 2E and G). An enlargem ent of this is shown in Color Plate 2F. In contrast, large areas of live cancer cells can be seen in the tum or from an anim al receiving LipT-p53 without radiation (Color Plate 2H) or LipT-pRo plus radiation (Color Plate 2I). These observation s were confirm ed by an experienced pathologist and are consistent with our previous results in studies with intratum orally injected, adenoviral vector carrying wt p53 in conjunction with radiation . These experim ents using a mouse cancer model dem onstrate that the com bination of transferrin-targeted systemic liposomal p53 gene therapy and conventiona l radiotherapy was markedly more effective than either treatment alone.
DISCUSSION
The development of viral and nonviral methods for the introduction of genes into cells in vivo has made therapeutic interventions involving gene therapy a reality. The introduction of wt p53 has been reported to suppress the growth of various types of malignancies, both in vitro and in mouse xenograft models. However, most of the in vivo results are obtained with viral p53 gene vectors and local administration (Fujiwara et al., 1994; Clayman et al., 1995; Liu et al., 1995; reviewed by Nielson and Maneval, 1998) . To overcome the limitations of the viral vectors, including the immunogenici ty and biosafety issues, and to realize the ultimate goal of systemic cancer gene therapy, nonviral gene delivery, especially ligand-directed tumortargeted system ic gene delivery, is an attractive alternative.
We have previously reported that wt p53 replacem ent by a nonviral gene delivery system, transferrin-liposome-DNA com plex, sensitized SCCHN cells to radiation in vitro (L. . This system was further optimized for systemic gene delivery in vivo. The results described above demonstrate that the transferrin-cationic liposome system can deliver genes systemically to xenograft tum ors in vivo, after intravenous administration. Twenty to 30% in vivo transfection efficiency was achieved via intravenous injection of the LipT-DNA complex. The LipT-mediate d p53 gene transfer apparently restored a functional apoptotic pathway in the SCCHN cells, thereby sensitizing the tumors to radiation therapy. Total tumor regression was observed in a nude mouse xenograft model of hum an SCCHN by a systemically delivered nonviral p53 vector in com bination with conventional radiation therapy. The combination of systemic LipT-p53 gene therapy and radiotherapy for SCCHN was markedly more effective than either treatment alone. This observation is consistent with our report of radiosensitization by folate-liposome-m ediated p53 gene therapy (Xu et al., 1999) . Although systemic LipT-p53 alone showed suppressive effects on tum or grow th, as observed here and also by others (Lesoon-Woo et al., 1995; M. Xu et al., 1997) , the tumor would ultimately recur after the treatment ceased. However, when LipT-p53 was combined with conventional radiotherapy, the established tumors regressed for up to 6 months after the end of treatment without recurrence. In the small residual "tum or nodules" that were static at less than 10% of the original tum or volume, only scar tissue and numerous macrophages or multinuclear Langerhans cells, in the process of surrounding and engulfing the remains of the dead tumor cells, were observed. Therefore, host macrophages might be involved in the treatment response (discussed below).
Lack of functional p53 results in the inability of the tumor cell to initiate programmed cell death (apoptosis) in response to DNA damage induced by radiation or other agents. Replacement of wild-type p53 should therefore restore the apoptotic response to irradiation . We have demonstrated previously that adenovirus mediated restoration of wt p53, in combination with radiation treatment, was able not only to inhibit tumor growth, but also to completely eliminate established radiation-resistant SCCHN xenograft tumors . This adenoviral wt p53 replacement also restored the G 1 checkpoint and the g radiation-induced apoptotic pathway in the tumor cells, and therefore sensitized the tumors to radiotherapy . The results presented here dem onstrate that (1) transferrin-liposome-medi ated p53 gene delivery can efficiently restore wt p53 function and the apoptotic pathway; (2) g irradiation can enhance and/or stabilize exogenous wt p53 expression in a radiation dose-dependent manner; (3) radiation induces a significant increase in p53-dependent apoptosis; and (4) this increase is radiation dose dependent and correlates with the exogenous wt p53 level in tumor cells. Further work is now underway to analyze the LipT-p53-m ediated changes in p53 downstream effectors or related molecules, e.g., p21 WAF1, Bcl-2, MDM2, p19ARF, etc., as well as cell cycle-related analysis.
The host defense system plays as important role in interactions between therapeutic regimens and target tissue, especially in the case of cancer gene therapy. With transferrin-targeted cationic liposome gene delivery, although only a fraction of tumor cells were transfected, the com bination therapy resulted in tumor regression without recurrence 6 months after the treatment stopped. Antiangiogenesi s may be an important mechanism involved in the system, as observed by M. . Liu et al. (1999) reported that system ic p53 gene delivery by cationic liposome inhibited angiogenesis by inducing endogenous thrombospondin -1 expression. Natural killer (NK) cells, which are abundant in the nude mouse, may also play a role in the tumor regression, as suggested by Hall et al. (1998) . As mentioned above, host macrophages are involved in the tumor response. Systemic LipT-p53 gene therapy plus radiation resulted in tumor cell death, likely through the induction of apoptosis. These apoptotic cells were phagocytosed by macrophages and possibly also by dendritic cells. The macrophages and dendritic cells can then serve as antigen-presenting cells to stimulate the host immune system (Lotze and Jaffe, 1999) . In the case of the athym ic nude mouse, which lacks T lymphocytes, NK cells may be involved. Peron et al. (1999) suggested a dendritic cell-NK cell link, in antitum or therapy. Currently, we are testing LipT-p53 systemic gene therapy in immune-com petent syngenic tum or models to explore the immunologica l and molecular mechanisms.
In conclusion, the transferrin-liposom e system is a highly efficient and tum or-specific gene delivery system both in vitro and in vivo. The replacem ent of wild-type p53 by LipT-p53 restored the wt p53 functional apoptotic pathway. The systemic delivery of LipT-p53 to established hum an SCCHN xenografts markedly sensitized the tum ors to radiation therapy. The combinatio n of system ic p53 gene therapy and conventional radiotherap y resulted in tumor regression and inhibition of their recurrence long-term . This strategy may provide a more effective treatment modality for human head and neck cancer.
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